| dbo:abstract
|
- سيناكالست (بالإنجليزية: Cinacalcet) هو دواء (يحاكي مفعول الكالسيوم في الأنسجة) من خلال تنشيط تفارغي الموجود في مختلف أعضاء الجسم. (ar)
- Cinacalcet (Handelsname in der EU Mimpara®; Hersteller Amgen) ist ein Arzneistoff zur Behandlung des primären und sekundären Hyperparathyreoidismus – einer Erkrankung der Nebenschilddrüse. (de)
- Cinacalcet, sold under the brand name Sensipar among others, is a medication used to treat tertiary hyperparathyroidism, parathyroid carcinoma, and primary hyperparathyroidism. The most common side effects include nausea (feeling sick) and vomiting. Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. Cinacalcet was approved in the United States in March 2004, and in the European Union in October 2004. It was the first allosteric G protein-coupled receptor modulator to enter the pharmaceutical market. In 2013, cinacalcet was the 76th top prescribed medicine in the United States. (en)
- Le cinacalcet est un médicament activant les récepteurs sensibles au calcium et utilisé, en particulier, dans l'insuffisance rénale chronique et l'hyperparathyroïdie. (fr)
- シナカルセト（Cinacalcet）はカルシウム受容体作動薬であり、二次性副甲状腺機能亢進症または副甲状腺癌等に伴う高カルシウム血症の治療に用いられる。その作用はアロステリックである。商品名レグパラ。 (ja)
- Il cinacalcet è un farmaco che agisce mimando l'azione del calcio e attivando allostericamente i recettori di membrana per tale elemento, espressi in vari organi e tessuti. È utilizzato nel trattamento dell'iperparatiroidismo secondario, una delle conseguenze della malattia renale cronica. È utilizzato anche nel trattamento dell'ipercalcemia nei pazienti affetti da carcinoma delle paratiroidi. È commercializzato dalla Amgen in Nord America e Australia come Sensipar e in Europa come Mimpara. (it)
- Cynakalcet (łac. Cinacalcetum) – lek kalcymimetyczny, obniżający stężenie parathormonu we krwi. (pl)
|
| dbo:alternativeName
| |
| dbo:bioavailability
| |
| dbo:casNumber
| |
| dbo:chEBI
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:medlinePlus
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 14872 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:bioavailability
|
- 20 (xsd:integer)
- increases if taken with food (en)
|
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chebi
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:eliminationHalfLife
| |
| dbp:excretion
| |
| dbp:f
| |
| dbp:h
| |
| dbp:image
|
- Cinacalcet ball-and-stick.png (en)
|
| dbp:iupacName
|
- -N-[1-ethyl]-3- (en)
- [3-phenyl]propan-1-amine (en)
|
| dbp:iupharLigand
| |
| dbp:kegg
| |
| dbp:legalAu
| |
| dbp:legalEu
| |
| dbp:legalStatus
| |
| dbp:legalUk
| |
| dbp:legalUs
| |
| dbp:licenceEu
| |
| dbp:licenceUs
| |
| dbp:medlineplus
| |
| dbp:metabolism
| |
| dbp:n
| |
| dbp:pregnancyAu
| |
| dbp:pregnancyUs
| |
| dbp:proteinBound
| |
| dbp:pubchem
| |
| dbp:pubchemsubstance
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- VDHAWDNDOKGFTD-MRXNPFEDSA-N (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- سيناكالست (بالإنجليزية: Cinacalcet) هو دواء (يحاكي مفعول الكالسيوم في الأنسجة) من خلال تنشيط تفارغي الموجود في مختلف أعضاء الجسم. (ar)
- Cinacalcet (Handelsname in der EU Mimpara®; Hersteller Amgen) ist ein Arzneistoff zur Behandlung des primären und sekundären Hyperparathyreoidismus – einer Erkrankung der Nebenschilddrüse. (de)
- Le cinacalcet est un médicament activant les récepteurs sensibles au calcium et utilisé, en particulier, dans l'insuffisance rénale chronique et l'hyperparathyroïdie. (fr)
- シナカルセト（Cinacalcet）はカルシウム受容体作動薬であり、二次性副甲状腺機能亢進症または副甲状腺癌等に伴う高カルシウム血症の治療に用いられる。その作用はアロステリックである。商品名レグパラ。 (ja)
- Il cinacalcet è un farmaco che agisce mimando l'azione del calcio e attivando allostericamente i recettori di membrana per tale elemento, espressi in vari organi e tessuti. È utilizzato nel trattamento dell'iperparatiroidismo secondario, una delle conseguenze della malattia renale cronica. È utilizzato anche nel trattamento dell'ipercalcemia nei pazienti affetti da carcinoma delle paratiroidi. È commercializzato dalla Amgen in Nord America e Australia come Sensipar e in Europa come Mimpara. (it)
- Cynakalcet (łac. Cinacalcetum) – lek kalcymimetyczny, obniżający stężenie parathormonu we krwi. (pl)
- Cinacalcet, sold under the brand name Sensipar among others, is a medication used to treat tertiary hyperparathyroidism, parathyroid carcinoma, and primary hyperparathyroidism. The most common side effects include nausea (feeling sick) and vomiting. Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. (en)
|
| rdfs:label
|
- Cinacalcet (en)
- سيناكالست (ar)
- Cinacalcet (de)
- Cinacalcet (fr)
- Cinacalcet (it)
- シナカルセト (ja)
- Cynakalcet (pl)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:treatment
of | |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
